Physician profile
Pedro Morales
NPI 1417020777
$15,019.38
in general payments reported to CMS, 2019-2025
37 companies · $891 in 2025
The $891 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,000 · 2020: $3,351 · 2021: $1,816 · 2022: $1,589 · 2023: $1,832 · 2024: $1,540 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,894.94 | 2019-2020 | |
| Abbvie INC. | $2,065.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,889.47 | 2019-2024 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $1,133.87 | 2019-2024 | Linzess |
| Janssen Biotech, INC. | $595.09 | 2019-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $547.88 | 2019-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $534.41 | 2019-2024 | Eohilia |
| Genzyme Corporation | $485.24 | 2022-2025 | |
| Ardelyx, INC. | $455.49 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $445.51 | 2019-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $397.69 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $303.02 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $254.38 | 2019-2024 | Suflave, Sutab |
| Redhill Biopharma INC. | $240.06 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $212.04 | 2021-2023 | Zeposia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $205.51 | 2020-2023 | |
| Lilly USA, LLC | $177.20 | 2024-2025 | Omvoh |
| Medtronic, INC. | $139.84 | 2023-2025 | Interstim, Gi Genius, Micra |
| Ionis Pharmaceuticals, INC. | $124.08 | 2025 | Tryngolza |
| Gilead Sciences, INC. | $90.49 | 2019-2023 | |
| Madrigal Pharmaceuticals | $79.63 | 2024-2025 | Resmetirom, Rezdiffra |
| Evoke Pharma, INC. | $70.62 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $70.53 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $67.16 | 2023-2024 | Voquezna |
| Pfizer INC. | $65.88 | 2019 | |
| Romark Laboratories, Lc | $64.17 | 2020 | |
| Apollo Endosurgery US INC | $60.98 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Ipsen Biopharmaceuticals, INC | $55.68 | 2024 | Iqirvo, Bylvay |
| Glaxosmithkline, LLC. | $53.86 | 2022-2023 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $50.09 | 2020 | |
| Ethicon US, LLC | $48.14 | 2019-2022 | |
| Vivus LLC | $37.40 | 2021-2022 | |
| Covidien LP | $24.64 | 2019 | |
| Ambu INC. | $23.30 | 2021 | |
| Pharmacosmos Therapeutics INC. | $22.99 | 2023 | Monoferric |
| Novartis Pharmaceuticals Corporation | $21.32 | 2019 | |
| Alfasigma USA, INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.